Lecture 17. Viruses that Infect Lymphocytes: EBV and HIV

Host - Pathogen Relationships

Host immune defense consistently fail to clear certain viral infections

Examine mechanisms pathogens use to evade immune defense

Contrasting host-pathogen relationships of two prototype infections

Epstein-Barr Virus (EBV)

Large DNA virus, e.g. herpesviruses have coevolved with their host species over many thousands to millions of years, are genetically stable, and persist in the immune host by shifting to a latent pattern of viral gene expression in response to T cell surveillance

Human immunodeficiency virus (HIV-1)

RNA viruses, e.g. HIV-1, are recently introduced into humans and have error-prone viral replication mechanisms that result in "swarms" of structurally distinct strains "quasispecies" that ultimately overwhelm the host by escaping from immune surveillance

Host-pathogen relationships Mechanisms of avoiding immune surveillance

1. Avoid recognition by cytotoxic T cells

 Evolution of viral strains that avoid presentation by MHC by mutating class I molecule peptide anchor amino acids or amino acids recognized by T cells in immunodominant peptides
 Blocking of antigen processing and presentation

- 2. Modification of the immune response e.g. release of anti-inflammatory cytokines, IL-10
- 3. Suppression of viral gene expression by the virus Change from productive to latent mode by selective pressure of immune response

Syndromes resulting from EBV infection

• Primary infection with EBV in childhood usually subclinical

• 25-70 % of newly infected adolescents and adults develop infectious mononucleosis: triad of fever, lymphadenopathy, and pharyngitis plus transient appearance of heterophil antibodies and activated clonally expanding CD8 cytotoxic anti EBV T cells ("atypical lymphocytosis")

Nasopharyngeal carcinoma, Gastric cancer subset
 B cell lymphomas: Burkitt's Lymphoma and immunoblastic lymphoma in immunosuppressed host, subset Hodgkin's disease

EBV is a B cell lymphotropic herpesvirus Stages of EBV infection

• First phase of infection is binding of an EBV surface glycoprotein to CD21 (CR2) expressed on the B cell membrane as a a BCR co-receptor complex with CD19; CD21 also expressed on some epithelial cells, accounting for tropism

• The binding of EBV to CD21/CR2 triggers Tindependent polyclonal B cell activation (CD23 and induction of Ig synthesis) and B cell proliferation resulting in T-independent release of heterophil and other antibodies (Rheumatoid factor, cold agglutinins, ANA)

•EBV enters the cell by receptor mediated endocytosis

Viruses often infect cells of the immune system sthrough receptors that are immunologically important

Initially EBV replicates as a productive lytic infection

 \bullet IgM antibodies to Viral Capsid Antigens (VCA) and Early Antigens (EA) are found at clinical presentation, indicating lytic replication and persists for 1-2 months.

 \bullet IgG anti VCA appears at time of clinical presentation and persists lifelong-"standard EBV titre"

•Antibodies to EA Peak at 3-4 weeks; marker of more severe disease

•Lytically infected cells are largely eliminated by EBVspecific cytotoxic cells (atypical lymphocytes), NK cells, interferon-mediated mechanisms and ADCC

• Antibodies to latent EB Nuclear Antigens (EBNA's) appear 3-6 weeks after initial infection; last lifelong ⁶

•EBV is maintained in its latent infective cycle as a multicopy circular 172Kd ds plasmid minichromosome with replication linked to B cell proliferation

•Latent proteins, consist of six nuclear antigens: EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, and EBNA leader protein (EBNA-LP) and three latent membrane proteins:

LMP1, LMP2A, and LMP2B

•CTL responses are Class I-restricted and are mainly directed against EBV nuclear antigens of the EBNA-3 family, and the latent membrane protein LMP 2

•EBNA1 binds to the EBV ori, initiating replication and also acting as a transcriptional enhancer

EBNA1 contains a gly-ala repeat region that inhibits the ATP motor of the proteasome, impeding further insertion of EBNA1 into the proteasome, thus halting its degradation, a strategy for avoiding surveillance

T cells play a crucial role in enforcing the maintenance of latency and thwart proliferation of EBV infected B cells by killing the B cell

B cell lymphoblastoid cell line (BLCL)

Express all latency genes, a pattern designated latency III, BLCL can be derived from nearly everyone

The characteristic BLCL phenotype consists of high expression of B cell activation markers CD23, CD30, CD39, and CD70, the cellular adhesion molecules LFA1 (CD11a/18), LFA3 (CD58), and intercellular adhesion molecule 1 ICAM1; (CD54)

Because of the adhesion molecules these BLCLs grow in large clumps in tissue culture

Immunoblastic lymphomas resembles the BLCL phenotype as well as express all latency genes; start polyclonal, then monoclonal Develop in solid organ or bone marrow transplant recipients receiving T cell immunsuppressive therapies

•Burkitt's lymphomas exhibit a different gene expression pattern "latency I"

•Only abundant EBNA1 transcription is found •Lymphoma cells display a distinct phenotype: CD10+

(CALLA) and CD77+ (BLA), but lack expression of activation and adhesion molecules

•In culture Burkitt B cell lines grow as dispersed single cells

The achilles' heel of the immune system

The T cell immune response to viruses often uses a very small number of different CD8 T cell clones directed to one or a few "immunodominant" peptides encoded by the viral genome, that are often presented by just one allelic type of an individual's HLA molecules

10

HLA-restricted CTL responses influence evolution of the host-pathogen relationship


HLA-A11distribution African 1.5%, Caucasian 6.9%, Asian 16.3% HLA-A11-positive Caucasians nearly always respond to two immunodominant HLA-A*1101 epitopes of the nuclear antigen EBNA3B (EBNA4): IVTDFSVIK 416 to 424


AVFDRKSDAK 399 to 408

These sequence motifs were often mutated in EBV strains in lowland Papua New Guinea and southern China, areas where more than 50% of individuals carry the HLA-A*1101 allele

All showed the same single point mutation, an A -> C mutation that produced a Lys -- Thr (K -> T) change in residue 424 of EBNA4 at position 9 of the CTL epitope

Loss of recognition of immunodominant epitope and ability to recognize EBV is a mechanism of escaping the CTL response






Host Response to HIV-1 infection


<u>First Phase:</u> CD8 T cell response of immune system *controls* initial destruction of memory/effector CD4 T cells, but does not eliminate infectious virus primarily located in monocytes and memory CD4 T cells Antibodies to HIV-1 are formed but these neither clear the infection nor are protective


- Acute illness- "flu-like"
- Clinical asymptomatic phase- 2-12 or more years

<u>Second Phase:</u> HIV-1 escapes the CD8 T cell response and mutations in the viral envelope now favor infection and destruction of naïve CD4 T cells


Acquired immune deficiency (AIDS) appears upon depletion of critical CD4 T cell subsets







HIV structures and HIV-1 mutational capacity, etc.



Chemokine Receptors:

CCR5

- Ligands: RANTES, MIP-1 α , MIP-1 β are produced in large quantities by <u>activated CD8</u> and CD4 T cells in the immune response to HIV and compete with R5 HIV binding to membrane receptor complex, blocking progress of the infection
- Distribution: CCR5 found on monocytes, DC and effector, memory or activated T cells, not naïve CD4 T cells
- Biology: CCR5 responsible for migration of memory and effector T cells, monocytes and dendritic cells to sites of inflammation
- Several CCR5 polymorphisms: e.g. ∆32 mutant allele render CCR5 unexpressed and incapable of binding HIV R5 strains. Homozygote frequency 1%, heterozygote ~10% in N.Euro. Caucasoids, but X4 strains are still infective

Chemokine Receptors: Coreceptors for HIV entry


CXCR4


- Ligand: Stromal derived growth factor 1 (SDF-1) produced by stromal cells. Competes with HIV binding, but not produced in inflammation or by T cells
- Receptor: expressed on monocytes, naïve T-cells, B-cells, etc. X4 virus preferentially infects naïve/activated T cells
 Biology: SDF-1 responsible for migration/homing of naïve T cells to lymph node

(Because T-cell lines only express CXCR4 coreceptors and respond to HIV infection by forming syncytia, earlier X4 strains were termed "syncytia inducing, or T-tropic") $_{\rm m}$

HIV strain early in infection

- *R5 is almost always the sexually transmissible form of* <u>the virus</u>
- Primary isolates from newly infected individuals are usually R5
- R5 strains mainly replicate in monocytes. Activated and memory T cells are infected, but at lower efficiency (old term = MT-tropic or monocytotropic)
- Therefore much of the viral load in earlier phase of HIV infection is in the monocytes and macrophages and the number of CD4 T cells though decreased, remains stable





Acute HIV-1 Infection "Flu-Like"

Clinical

- Headache, retro-orbital pain, myalgias, pharyngitis, fever, Nonpruritic maculopapular rash in first 1-3 weeks Adenopathy and malaise may last for several months
- Transient thrombocytopenia and CD4 T-cell lymphopenia

Viral

- Rapid appearance of marked viremia with an R5 strain
- infecting monocytes and memory CD4 T cells
- This results in acute CD4 T-cell lymphopenia
- Integration in memory CD4 T cells provides a long-lived reservoir where HIV can remain latent
- Structurally the initial virus strain has no, or very limited diversity $^{\rm 24}$

Acute Infection


Development of anti HIV Immune Response


- With onset of a CD8 T-cell immune response viremia falls from ${\sim}5x10^6$ /ml to ${<}10^4$ /ml
- \bullet The CD4 T-cell count rises from ~400 to >800/ μ
- Degree of viral suppression and return of CD4 T cell levels (set point !) varies and correlates with the length of the asymptomatic period
- HIV species begin to diversify, viral variants appear reflecting successful attempts to escape the suppression of the CD8 T cell response
- The virus mainly persists in monocytes / macrophages _____


CD8 T-cell Response to HIV-1

- Establishes asymptomatic phase of infection
- Specific CD8 CTL <u>lysis</u> of HIV- infected target cells (macrophages and CD4 T cells) via perforin pathway and/ or apoptosis via upregulation of *fas* ligand
- Strong <u>inhibition</u> of viral infectivity by release of chemokines (MIP-1 α/β , RANTES) that bind to CCR5 and compete with coreceptor dependent entry of R5 HIV-1
- Release of IFN- γ and secondarily TNF- $\alpha,$ decrease LTR-driven transcription

26







Immune Responses in asymptomatic phase

Depends on a relatively few CD8 T cell clones


- Maintenance of a few CD8 T-cell expanded memory/ effector CTL clones, each comprising 1-5% of CD8 T cell repertoire
- Clones each recognize different immunodominant HIV peptides, great individual variation in number and particular peptide recognized
- More clones = generally good outlook for long asymptomatic period (>12yrs), fewer clones =rapid progression of HIV infection (<2yrs)

Long term non progressors

- A subset of infected individuals that remain asymptomatic for >12 years
- Particular HLA types, e.g. HLA-B27, B57, etc.
- Low levels of plasma virions, CD4 counts >500/ul
- High CD8 T-cell counts, may be > 3,000/ul
- High chemokine release (RANTES, MIP)
- CTL response is against critical conserved region of HIV gag, env, pol that cannot readily be mutated without loss of viral function-This appears to be the key factor !

The environment formed by peptide binding properties of MHC molecules influences evolution of the HIV infection HLA alleles influence the number of peptides in a protein that can be recognized (Example HIV envelope protein)

Allele:HLA-B*27052		HLA-B*3501	HLA-B*0702
Motif XRXXXXX	XX [KRYL]	XPXXXXXXY	XPXXXXXL
Peptides able to bind each allelic molecule			
I RGKVQKE Y	K R RVVQRE K		DPNPQEVVL
IRPVVSTQL	A R ILAVER Y		K P CVKLTP L
T R PNNNTR K	E R DRDRSI R		R P VVSTQL L
I R IQRGPG R	LRSLCLFSY		SPLSFQTHL
SRAKWNNTL	TRIVELLGR		I P RRIRQG L
L R EQFGNN K	C R AIRHIP R		
F R PGGGDM R	I R QGLERI L		
WRSELYKYK			
# of peptides	15	0	6 ³²



Basis of outcome with HLA type


HLA-B35 RAPID PROGRESSION


xPxxxxxY peptides recognized, if any, are in <u>non</u> critical parts of HIV genome permitting mutations in MHC anchor residues. Peptides weak stimulators Rapid viral replication and evolution not restrained

HLA-B27 SLOW PROGRESSION

 $x Rxxxxxx [{\it KRYL}] \ peptides \ recognized \ are \ often \ in \ critical \ parts \ of \ HIV \ genome \ and \ mutations \ not \ permitted \ in \ MHC \ anchor \ or \ TCR \ recognition \ residues \ set \ and \ set \ set \ and \ set \$

Viral replication and evolution greatly slowed





impairment of CD4 T-cell compartment Loss of the "epitope war"³⁶

Reasons for CD4 T cell loss in HIV-1 Infection

During asymptomatic phase and transition to AIDS Accelerated loss in number of CD4 T cells

- Activation of large numbers of mature and naïve CD4
- T cells by cytokines, etc. during antiviral response
- (Bystander activation, homeostatic regulation) leads to

loss of repertoire by physiologic apoptosis

- $\bullet\,$ Thymic derangement results in failure to generate new naïve CD4 T cells to repopulate repertoire
- CD8 T cell killing of infected CD4 T cells
- ADCC by NK cells, etc. to infected CD4 T cells

37

Another reason for CD4 T cell loss CD4 T cell activation initiates HIV replication T cell activation causes, among other effects, a marked increase in cyclin T1, NFAT and NFxB Transcriptional activation of HIV-1 gene expression This links viral expression to T cell activation

38

AIDS is the consequence of progressive CD4 loss

T cell immune function progressively deteriorates reflecting the central role of CD4 T cells

Stages:

- Loss of antigen-specific clonal responses (in vitro proliferation and skin test to various antigens, including those from immunizations
- •Loss of ability to generate new CD8 T cell responses
- •Loss of Mixed Lymphocyte Culture responsiveness
- •Loss of PHA responsiveness

AIDS is the consequence of progressive CD4 loss

Appearance of different infections as severity of immune deficiency increases

Candida (Thrush)

Salmonella - microbial persistence (Reactive arthritis?) Mycobacterium tuberculosis reactivation, Cryptosporidium

Activation of latent herpes zoster

Tat and cyclin T1 binding to TAR activate leading to phosphorylation of the C-te domain (CTD) of RNAPII and effective eld

EBV reactivation and development of polyclonal lymphomas, Kaposi's sarcoma (HHV-8)

Pneumocystis carinii

Progressive cytomegalovirus infections, M. avium complex

HIV virus vaccines have failed, Why?

- Immunization with rENV produce neutralizing antibodies
- But neutralizing antibodies induced by immunization fail to protect as shown in multiple trials
- A live attenuated virus has not yet proved achievable
- The second larger issue is heterogeneity of HIV strains, need many immunodominant peptides directed to critical regions of viral genome because no cross protection
- Some strains, mainly X4 tropic have evolved to circumvent MHC presentation by some common alleles. With high numbers of infected individuals there is increasing chance of infecting a person with the same HLA by a strain evolved to avoid immunosurveillance
- Recombinant live virus vaccines are under trial, but a major issue is providing HIV peptides able to bind divergent MHC class I of a large proportion of the population

But vCP205 a recombinant live virus canarypox vector vaccine expressing gp41, Gag and Protease HIV genes addresses- in theory- all of these concerns

42

Case Report of a failure of a recombinant live vaccine Betts et al. PNAS 2005, **102**:4512

Case # 202-T07, an HLA-B*2705 HIV-negative male homosexual

vCP205 canarypox vector expressing gp41, Gag and Protease vaccination course given over 5 months

Immune response documented to two CD8 epitopes and one CD4 epitope including response to the HLA-B*2705-restricted Gag peptide KRWIIIGLNK in central and peripheral memory/effector CD8 T cells CD28+CCR7+CD45RO+ and CD28-CCR7-CD45RO-

Approximately 18 months later 202-T07 had unprotected anal intercourse with an undisclosed HIV+ partner $$_{\rm 43}$$

Shortly thereafter, he developed flu-like symptoms and was then found to be positive for HIV antibodies, with a plasma viral load of 234,695 HIV-1 virions/ml

The acute infection induced a recall response to the B*2705-restricted clone, expanding it from 0.05% Of CD8 T cells to 9.8% of CD8 T cells, and this remained the dominant clonotype during acute infection

During the acute infection period there was no evidence of viral escape, but by 32 months after diagnosis the predominant virion-encoded Gag peptide sequence mutated from KRWIIIGLNK to KGWIIIGLNK, thus thwarting binding and presentation of the peptide by HLA-B*2705

Viral escape this early is extremely unusual, the average time to development of this escape mutation in unvaccinated individuals is >9 years

Moreover, the average survival until AIDS in an HLA- $B^{\star}2705$ individual is >14 years

His CD4 T cell count continues to decline, presently 400 cells / μ l at 32 months post infection, and viral titre remains high, despite optimal anti-retroviral therapy

The authors raise the strong possibility that a vaccine developed according to the best notions of current immunological knowledge not only did not protect against HIV infection but accelerated development of the escape mutation in the vaccinated individual, thus hastening progression of the viral infection ⁴⁵